指南与共识耳科与耳神经小儿耳鼻咽喉

突发性听力损失临床实践指南(更新版)执行摘要

Clinical Practice Guideline: Sudden Hearing Loss (Update) Executive Summary.
指南 / 共识 · Otolaryngol Head Neck Surg · 2019-01-01

本指南更新由美国耳鼻咽喉头颈外科学会制定,针对≥18岁成人突发感音神经性听力损失(SSNHL)提供循证推荐。重点在于区分感音神经性与传导性听力损失、识别非特发性病因、及时听力学确诊(14天内)、排除常规CT和实验室检查、不推荐抗病毒/溶栓/血管活性药物,并规范激素、高压氧及挽救治疗时机。

要点

  • 首诊即区分感音神经性与传导性听力损失,并评估双侧、复发及局灶神经体征。
  • 症状出现14天内尽快行听力学检查确诊,并评估耳蜗后病变(MRI或ABR)。
  • 不常规行头部CT、实验室检查,不处方抗病毒/溶栓/血管扩张/血管活性药物。

核心结论

  • 及时识别和处理特发性突发感音神经性听力损失可能改善听力恢复和生活质量。
  • 指南旨在提高诊断准确性、促进及时干预、减少不必要检查和影像、改善听力康复结局。

研究设计与样本

  • 按AAO-HNSF临床实践指南开发手册第三版,组建多学科指南更新组。
  • 进行了系统文献综述,纳入10部临床实践指南、29篇新系统综述和36项新随机对照试验。
  • 目标人群为18岁及以上突发感音神经性听力损失成人,主要为特发性者。

主要发现

  • 突发感音神经性听力损失年发病率5-27/10万,美国每年约66,000新发病例。
  • 超过90%的突发感音神经性听力损失为特发性。
  • 指南更新组给出了强推荐、强不推荐、推荐和可选推荐的关键行动声明。

关键数值与推荐

  • 强推荐:首诊时区分感音神经性与传导性听力损失(KAS 1)。
  • 强推荐:向患者教育自然病程、干预获益与风险及证据局限性(KAS 7)。
  • 强推荐:对残留听力损失和/或耳鸣者咨询听力康复和其他支持措施(KAS 13)。
  • 强不推荐:初诊疑诊SSNHL不常规行头部CT(KAS 3)、不常规行实验室检查(KAS 5)、不常规处方抗病毒/溶栓/血管扩张/血管活性药物(KAS 11)。
  • 推荐:症状出现14天内尽快行听力学检查确诊(KAS 4);通过MRI或ABR评估耳蜗后病变(KAS 6);症状出现2-6周不完全恢复者提供鼓室内激素治疗(KAS 10);治疗结束及结束后6个月内复查听力学(KAS 12)。

临床怎么用

  • 首诊通过病史和体格检查识别双侧、复发或局灶神经体征,以筛查非特发性病因。
  • 疑诊SSNHL时14天内完成听力学确诊,并安排MRI或ABR排除耳蜗后病变。
  • 避免常规头部CT和实验室检查,不常规使用抗病毒、溶栓、血管扩张或血管活性药物。
  • 症状出现2周内可考虑初始激素治疗;2周内可考虑高压氧联合激素;1个月内可考虑高压氧联合激素作为挽救治疗。
  • 对不完全恢复者(2-6周)提供鼓室内激素,治疗结束及6个月内复查听力。

局限性

  • 指南主要针对成人特发性突发感音神经性听力损失,不适用于儿童或非特发性人群。
  • 部分关键行动声明仅为可选推荐,证据确定性有限。
  • 原文未报告具体阈值、剂量、样本量或P值等细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Sudden hearing loss is a frightening symptom that often prompts an urgent or emergent visit to a health care provider. It is frequently, but not universally, accompanied by tinnitus and/or vertigo. Sudden sensorineural hearing loss affects 5 to 27 per 100,000 people annually, with about 66,000 new cases per year in the United States. This guideline update provides evidence-based recommendations for the diagnosis, management, and follow-up of patients who present with sudden hearing loss. It focuses on sudden sensorineural hearing loss in adult patients aged 18 and over and primarily on those with idiopathic sudden sensorineural hearing loss. Prompt recognition and management of sudden sensorineural hearing loss may improve hearing recovery and patient quality of life. The guideline update is intended for all clinicians who diagnose or manage adult patients who present with sudden hearing loss. PURPOSE: The purpose of this guideline update is to provide clinicians with evidence-based recommendations in evaluating patients with sudden hearing loss and sudden sensorineural hearing loss, with particular emphasis on managing idiopathic sudden sensorineural hearing loss. The guideline update group recognized that patients enter the health care system with sudden hearing loss as a nonspecific primary complaint. Therefore, the initial recommendations of this guideline update address distinguishing sensorineural hearing loss from conductive hearing loss at the time of presentation with hearing loss. They also clarify the need to identify rare, nonidiopathic sudden sensorineural hearing loss to help separate those patients from those with idiopathic sudden sensorineural hearing loss, who are the target population for the therapeutic interventions that make up the bulk of the guideline update. By focusing on opportunities for quality improvement, this guideline should improve diagnostic accuracy, facilitate prompt intervention, decrease variations in management, reduce unnecessary tests and imaging procedures, and improve hearing and rehabilitative outcomes for affected patients. METHODS: Consistent with the American Academy of Otolaryngology-Head and Neck Surgery Foundation's Clinical Practice Guideline Development Manual, Third Edition, the guideline update group was convened with representation from the disciplines of otolaryngology-head and neck surgery, otology, neurotology, family medicine, audiology, emergency medicine, neurology, radiology, advanced practice nursing, and consumer advocacy. A systematic review of the literature was performed, and the prior clinical practice guideline on sudden hearing loss was reviewed in detail. Key action statements (KASs) were updated with new literature, and evidence profiles were brought up to the current standard. Research needs identified in the original clinical practice guideline and data addressing them were reviewed. Current research needs were identified and delineated. RESULTS: The guideline update group made strong recommendations for the following: clinicians should distinguish sensorineural hearing loss from conductive hearing loss when a patient first presents with sudden hearing loss (KAS 1); clinicians should educate patients with sudden sensorineural hearing loss about the natural history of the condition, the benefits and risks of medical interventions, and the limitations of existing evidence regarding efficacy (KAS 7); and clinicians should counsel patients with sudden sensorineural hearing loss who have residual hearing loss and/or tinnitus about the possible benefits of audiological rehabilitation and other supportive measures (KAS 13). These strong recommendations were modified from the initial clinical practice guideline for clarity and timing of intervention. The guideline update group made strong recommendation against the following: clinicians should not order routine computed tomography of the head in the initial evaluation of a patient with presumptive sudden sensorineural hearing loss (KAS 3); clinicians should not obtain routine laboratory tests in patients with sudden sensorineural hearing loss (KAS 5); and clinicians should not routinely prescribe antivirals, thrombolytics, vasodilators, or vasoactive substances to patients with sudden sensorineural hearing loss (KAS 11). The guideline update group made recommendations for the following: clinicians should assess patients with presumptive sudden sensorineural hearing loss through history and physical examination for bilateral sudden hearing loss, recurrent episodes of sudden hearing loss, and/or focal neurologic findings (KAS 2); in patients with sudden hearing loss, clinicians should obtain, or refer to a clinician who can obtain, audiometry as soon as possible (within 14 days of symptom onset) to confirm the diagnosis of sudden sensorineural hearing loss (KAS 4); clinicians should evaluate patients with sudden sensorineural hearing loss for retrocochlear pathology by obtaining a magnetic resonance imaging or auditory brainstem response (KAS 6); clinicians should offer, or refer to a clinician who can offer, intratympanic steroid therapy when patients have incomplete recovery from sudden sensorineural hearing loss 2 to 6 weeks after onset of symptoms (KAS 10); and clinicians should obtain follow-up audiometric evaluation for patients with sudden sensorineural hearing loss at the conclusion of treatment and within 6 months of completion of treatment (KAS 12). These recommendations were clarified in terms of timing of intervention and audiometry, as well as method of retrocochlear workup. The guideline update group offered the following KASs as options: clinicians may offer corticosteroids as initial therapy to patients with sudden sensorineural hearing loss within 2 weeks of symptom onset (KAS 8); clinicians may offer, or refer to a clinician who can offer, hyperbaric oxygen therapy combined with steroid therapy within 2 weeks of onset of sudden sensorineural hearing loss (KAS 9a); and clinicians may offer, or refer to a clinician who can offer, hyperbaric oxygen therapy combined with steroid therapy as salvage therapy within 1 month of onset of sudden sensorineural hearing loss (KAS 9b). DIFFERENCES FROM PRIOR GUIDELINE: Incorporation of new evidence profiles to include quality improvement opportunities, confidence in the evidence, and differences of opinion Included 10 clinical practice guidelines, 29 new systematic reviews, and 36 new randomized controlled trials Highlights the urgency of evaluation and initiation of treatment, if treatment is offered, by emphasizing the time from symptom occurrence Clarification of terminology by changing potentially unclear statements; use of the term sudden sensorineural hearing loss to mean idiopathic sudden sensorineural hearing loss to emphasize that over 90% of sudden sensorineural hearing loss is idiopathic sudden sensorineural hearing loss and to avoid confusion in nomenclature for the reader Changes to the key action statements (KASs) from the original guideline: KAS 1: When a patient first presents with sudden hearing loss, conductive hearing loss should be distinguished from sensorineural. KAS 2: The utility of history and physical examination when assessing for modifying factors is emphasized. KAS 3: The word routine is added to clarify that this statement addresses a nontargeted head computed tomography scan that is often ordered in the emergency room setting for patients presenting with sudden hearing loss. It does not refer to targeted scans such as a temporal bone computed tomography scan to assess for temporal bone pathology. KAS 4: The importance of audiometric confirmation of hearing status as soon as possible and within 14 days of symptom onset is emphasized. KAS 5: New studies were added to confirm the lack of benefit of nontargeted laboratory testing in sudden sensorineural hearing loss. KAS 6: Audiometric follow-up is excluded as a reasonable workup for retrocochlear pathology. Magnetic resonance imaging, computed tomography scan if magnetic resonance imaging cannot be done, or, secondarily, auditory brainstem response evaluation are the modalities recommended. A time frame for such testing is not specified, nor is it specified which clinician should be ordering this workup; however, it is implied that it would be the general or subspecialty otolaryngologist. KAS 7: The importance of shared decision making is highlighted, and salient points are emphasized. KAS 8: The option for corticosteroid intervention within 2 weeks of symptom onset is emphasized. KAS 9: Changed to KAS 9a and 9b; hyperbaric oxygen therapy remains an option but only when combined with steroid therapy for either initial treatment (9a) or for salvage therapy (9b). The timing is within 2 weeks of onset for initial therapy and within 1 month of onset of sudden sensorineural hearing loss for salvage therapy. KAS 10: Intratympanic steroid therapy for salvage is recommended within 2 to 6 weeks following onset of sudden sensorineural hearing loss. The time to treatment is defined and emphasized. KAS 11: Antioxidants were removed from the list of interventions that the clinical practice guideline recommends against using. KAS 12: Follow-up audiometry at conclusion of treatment and also within 6 months posttreatment is added. KAS 13: This statement on audiologic rehabilitation includes patients who have residual hearing loss and/or tinnitus who may benefit from treatment. Addition of an algorithm outlining KASs Enhanced emphasis on patient education and shared decision making with tools provided to assist in the same.

来源:Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Chandrasekhar SS, Tsai Do BS, Schwartz SR, et al. Clinical Practice Guideline: Sudden Hearing Loss (Update) Executive Summary. Otolaryngol Head Neck Surg. 2019. PMID: 31369349. doi:10.1177/0194599819859883

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。